Literature DB >> 27862220

7-Dehydrocholesterol (7-DHC), But Not Cholesterol, Causes Suppression of Canonical TGF-β Signaling and Is Likely Involved in the Development of Atherosclerotic Cardiovascular Disease (ASCVD).

Shuan Shian Huang1, I-Hua Liu2, Chun-Lin Chen3, Jia-Ming Chang2, Frank E Johnson4, Jung San Huang5.   

Abstract

For several decades, cholesterol has been thought to cause ASCVD. Limiting dietary cholesterol intake has been recommended to reduce the risk of the disease. However, several recent epidemiological studies do not support a relationship between dietary cholesterol and/or blood cholesterol and ASCVD. Consequently, the role of cholesterol in atherogenesis is now uncertain. Much evidence indicates that TGF-β, an anti-inflammatory cytokine, protects against ASCVD and that suppression of canonical TGF-β signaling (Smad2-dependent) is involved in atherogenesis. We had hypothesized that cholesterol causes ASCVD by suppressing canonical TGF-β signaling in vascular endothelium. To test this hypothesis, we determine the effects of cholesterol, 7-dehydrocholesterol (7-DHC; the biosynthetic precursor of cholesterol), and other sterols on canonical TGF-β signaling. We use Mv1Lu cells (a model cell system for studying TGF-β activity) stably expressing the Smad2-dependent luciferase reporter gene. We demonstrate that 7-DHC (but not cholesterol or other sterols) effectively suppresses the TGF-β-stimulated luciferase activity. We also demonstrate that 7-DHC suppresses TGF-β-stimulated luciferase activity by promoting lipid raft/caveolae formation and subsequently recruiting cell-surface TGF-β receptors from non-lipid raft microdomains to lipid rafts/caveolae where TGF-β receptors become inactive in transducing canonical signaling and undergo rapid degradation upon TGF-β binding. We determine this by cell-surface 125 I-TGF-β-cross-linking and sucrose density gradient ultracentrifugation. We further demonstrate that methyl-β-cyclodextrin (MβCD), a sterol-chelating agent, reverses 7-DHC-induced suppression of TGF-β-stimulated luciferase activity by extrusion of 7-DHC from resident lipid rafts/caveolae. These results suggest that 7-DHC, but not cholesterol, promotes lipid raft/caveolae formation, leading to suppression of canonical TGF-β signaling and atherogenesis. J. Cell. Biochem. 118: 1387-1400, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  7-DHC; CANONICAL TGF-β SIGNALING; CHOLESTEROL; LIPID RAFTS/CAVEOLAE; NON-LIPID RAFT MICRODOMAINS

Mesh:

Substances:

Year:  2016        PMID: 27862220      PMCID: PMC6123222          DOI: 10.1002/jcb.25797

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  68 in total

1.  A NEWLY RECOGNIZED SYNDROME OF MULTIPLE CONGENITAL ANOMALIES.

Authors:  D W SMITH; L LEMLI; J M OPITZ
Journal:  J Pediatr       Date:  1964-02       Impact factor: 4.406

Review 2.  Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.

Authors:  James K Liao
Journal:  Am J Cardiol       Date:  2005-09-05       Impact factor: 2.778

Review 3.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

4.  Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome.

Authors:  P E Jira; R A Wevers; J de Jong; E Rubio-Gozalbo; F S Janssen-Zijlstra; A F van Heyst; R C Sengers; J A Smeitink
Journal:  J Lipid Res       Date:  2000-08       Impact factor: 5.922

5.  Identification of 8-dehydrocholesterol (cholesta-5,8-dien-3 beta-ol) in patients with Smith-Lemli-Opitz syndrome.

Authors:  A K Batta; G S Tint; S Shefer; D Abuelo; G Salen
Journal:  J Lipid Res       Date:  1995-04       Impact factor: 5.922

6.  Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors.

Authors:  Chun-Lin Chen; Shuan Shian Huang; Jung San Huang
Journal:  J Cell Physiol       Date:  2008-04       Impact factor: 6.384

7.  Cellular heparan sulfate negatively modulates transforming growth factor-beta1 (TGF-beta1) responsiveness in epithelial cells.

Authors:  Chun-Lin Chen; Shuan Shian Huang; Jung San Huang
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

8.  Caveolar and lipid raft localization of the growth hormone receptor and its signaling elements: impact on growth hormone signaling.

Authors:  Ning Yang; Yao Huang; Jing Jiang; Stuart J Frank
Journal:  J Biol Chem       Date:  2004-03-08       Impact factor: 5.157

9.  Nerve growth factor/p75 neurotrophin receptor-mediated sensitization of rat sensory neurons depends on membrane cholesterol.

Authors:  Y H Zhang; R Khanna; G D Nicol
Journal:  Neuroscience       Date:  2013-06-27       Impact factor: 3.590

Review 10.  Transforming growth factor-beta regulation of immune responses.

Authors:  Ming O Li; Yisong Y Wan; Shomyseh Sanjabi; Anna-Karin L Robertson; Richard A Flavell
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

View more
  3 in total

1.  Pentabromophenol suppresses TGF-β signaling by accelerating degradation of type II TGF-β receptors via caveolae-mediated endocytosis.

Authors:  Chun-Lin Chen; Pei-Hua Yang; Yu-Chen Kao; Pei-Yu Chen; Chih-Ling Chung; Shih-Wei Wang
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

2.  Sphingomyelin synthase 1 regulates the epithelial‑to‑mesenchymal transition mediated by the TGF‑β/Smad pathway in MDA‑MB‑231 cells.

Authors:  Shuang Liu; Huan Hou; Panpan Zhang; Yifan Wu; Xuanhong He; Hua Li; Nianlong Yan
Journal:  Mol Med Rep       Date:  2018-12-04       Impact factor: 2.952

3.  Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation.

Authors:  Wang Shih-Wei; Chung Chih-Ling; Yu-Chen Kao; René Martin; Hans-Joachim Knölker; Meng-Shin Shiao; Chun-Lin Chen
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.